Stem-like cells in tumors are capable of self-renewal and pluri-differentiation; they are thought to play important roles in tumor initiation and maintenance. Stem-like cells in malignant glioma express CD133. We examined samples from human pituitary adenoma, a generally benign neoplasm, for CD133 expression using routine immunohistochemical and biochemical methods. Our study of 70 pituitary adenomas (clinically nonfunctioning adenomas and growth hormone-, prolactin-, adrenocorticotropic hormone-, and thyroid-stimulating hormone-producing adenomas) showed that 18 (25.7%) expressed CD133. This rate was higher in clinically nonfunctioning (33.3%) than functioning adenomas (12.0%) (p = 0.085). Real-time PCR assay revealed the expression of CD133 mRNA in samples immunohistochemically positive for CD133. Neither the patient age and gender, nor the tumor size or postoperative recurrence rate correlated with CD133 positivity. CD133+ cells ubiquitously coexpressed CD34, nestin, and VEGFR2 (KDL1). S-100 and GFAP were not coexpressed with CD133. Chromogranin A, Pit-1, SF-1, and NeuroD1 were immune-negative, indicating that CD133+ cells did not have the potential to differentiate into functional endocrine cells. Our data suggest that the expression of CD133 in pituitary adenomas is related to immature endothelial progenitor cells that may play a role in the neovascularization of pituitary adenomas. Further studies are needed to elucidate the significance of CD133+ cells with respect to neovascularization and their sustainable growth in pituitary adenomas.

Keywords:
Pituitary adenoma, CD133, Endothelial progenitor, Angiogenesis, Tumor stem cell
1.
Niveiro M, Aranda FI, Peiro G, Alenda C, Pico A: Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas. Hum Pathol 2005;36:1090–1095.
2.
Lloyd RV, Scheithauer BW, Kovacs K, Roche PC: The immunophenotype of pituitary adenomas. Endocr Pathol 1996;7:145–150.
3.
Xu Q, Yuan X, Tunici P, Liu G, Fan X, Xu M, Hu J, Hwang JY, Farkas DL, Black KL, Yu JS: Isolation of tumour stem-like cells from benign tumours. Br J Cancer 2009;101:303–311.
4.
Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997;90:5002–5012.
5.
Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730–737.
6.
Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R: Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111–115.
7.
Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT: CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004;117:3539–3545.
8.
Florek M, Haase M, Marzesco AM, Freund D, Ehninger G, Huttner WB, Corbeil D: Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res 2005;319:15–26.
9.
Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB: Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821–5828.
10.
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB: Identification of human brain tumour initiating cells. Nature 2004;432:396–401.
11.
Kang MK, Kang SK: Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. Stem Cells Dev 2007;16:837–847.
12.
Hambardzumyan D, Squatrito M, Holland EC: Radiation resistance and stem-like cells in brain tumors. Cancer Cell 2006;10:454–456.
13.
Ribatti D: The involvement of endothelial progenitor cells in tumor angiogenesis. J Cell Mol Med 2004;8:294–300.
14.
Hristov M, Weber C: Endothelial progenitor cells in vascular repair and remodeling. Pharmacol Res 2008;58:148–151.
15.
Chen J, Hersmus N, Van Duppen V, Caesens P, Denef C, Vankelecom H: The adult pituitary contains a cell population displaying stem/progenitor cell and early embryonic characteristics. Endocrinology 2005;146:3985–3998.
16.
Pomyje J, Zivny J, Sefc L, Plasilova M, Pytlik R, Necas E: Expression of genes regulating angiogenesis in human circulating hematopoietic cord blood CD34+/CD133+ cells. Eur J Haematol 2003;70:143–150.
17.
Mustonen T, Alitalo K: Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 1995;129:895–898.
18.
Hilbe W, Dirnhofer S, Oberwasserlechner F, Schmid T, Gunsilius E, Hilbe G, Woll E, Kahler CM: CD133-positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol 2004;57:965–969.
19.
Bruno S, Bussolati B, Grange C, Collino F, Graziano ME, Ferrando U, Camussi G: CD133+ renal progenitor cells contribute to tumor angiogenesis. Am J Pathol 2006;169:2223–2235.
20.
Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM: Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964–967.
21.
Gehling UM, Ergun S, Schumacher U, Wagener C, Pantel K, Otte M, Schuch G, Schafhausen P, Mende T, Kilic N, Kluge K, Schafer B, Hossfeld DK, Fiedler W: In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 2000;95:3106–3112.
22.
Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA, Rafii S: Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors. Blood 2000;95:952–958.
23.
Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A, Fujita Y, Kothari S, Mohle R, Sauvage LR, Moore MA, Storb RF, Hammond WP: Evidence for circulating bone marrow-derived endothelial cells. Blood 1998;92:362–367.
24.
Lin Y, Weisdorf DJ, Solovey A, Hebbel RP: Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000;105:71–77.
25.
Kanayasu-Toyoda T, Yamaguchi T, Oshizawa T, Hayakawa T: CD31 (PECAM-1)-bright cells derived from AC133-positive cells in human peripheral blood as endothelial-precursor cells. J Cell Physiol 2003;195:119–129.
26.
Kaushal S, Amiel GE, Guleserian KJ, Shapira OM, Perry T, Sutherland FW, Rabkin E, Moran AM, Schoen FJ, Atala A, Soker S, Bischoff J, Mayer JE Jr: Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo. Nat Med 2001;7:1035–1040.
27.
Wijelath ES, Rahman S, Murray J, Patel Y, Savidge G, Sobel M: Fibronectin promotes VEGFR-induced CD34 cell differentiation into endothelial cells. J Vasc Surg 2004;39:655–660.
28.
Randeva HS, Schoebel J, Byrne J, Esiri M, Adams CB, Wass JA: Classical pituitary apoplexy: clinical features, management and outcome. Clin Endocrinol (Oxf) 1999;51:181–188.
29.
Raappana A, Koivukangas J, Ebeling T, Pirila T: Incidence of pituitary adenomas in northern Finland in 1992–2007. J Clin Endocrinol Metab 2010;95:4268–4275.
30.
Navarro-Sobrino M, Rosell A, Hernandez-Guillamon M, Penalba A, Ribo M, Alvarez-Sabin J, Montaner J: Mobilization, endothelial differentiation and functional capacity of endothelial progenitor cells after ischemic stroke. Microvasc Res 2010;80:317–323.
31.
Urbich C, Dimmeler S: Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004;95:343–353.
32.
Friedrich EB, Walenta K, Scharlau J, Nickenig G, Werner N: CD34–/CD133+/VEGFR- 2+ endothelial progenitor cell subpopulation with potent vasoregenerative capacities. Circ Res 2006;98:e20–e25.
33.
Mokry J, Nemecek S: Cerebral angiogenesis shows nestin expression in endothelial cells. Gen Physiol Biophys 1999;18(suppl 1):25–29.
34.
Amoh Y, Yang M, Li L, Reynoso J, Bouvet M, Moossa AR, Katsuoka K, Hoffman RM: Nestin-linked green fluorescent protein transgenic nude mouse for imaging human tumor angiogenesis. Cancer Res 2005;65:5352–5357.
35.
Johnson MD, Fan X, Bourne P, Walters D: Neuronal differentiation and expression of neural epitopes in pituitary adenomas. J Histochem Cytochem 2007;55:1265–1271.
36.
Koutourousiou M, Kontogeorgos G, Wesseling P, Grotenhuis AJ, Seretis A: Collision sellar lesions: experience with eight cases and review of the literature. Pituitary 2009;13:8–17.
37.
Sabel MC, Hans VH, Reifenberger G: Mixed gangliocytoma/pituitary adenoma. Arch Neurol 2000;57:587–588.
38.
Horvath E, Kovacs K: Folliculo-stellate cells of the human pituitary: a type of adult stem cell? Ultrastruct Pathol 2002;26:219–228.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.